Biolase (BIOL) Misses Q3 EPS by 47c

Biolase (NASDAQ: BIOL) reported Q3 EPS of ($1.10), $0.47 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $12.01 million versus the consensus estimate of $10.53 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c